Pebble Island, The Falklands War 1982


This revised anniversary edition is a very welcome edition, packed with insight and images. The Royal Navy assembled a Task Force in double quick time, sailed 8,000 miles and gave the Argentine bandits a drubbing – classic Empire Strikes Back. – Very Highly Recommended.

Leave.EU weekly update – UK fisheries betrayed, EU court rules against itself and the Tory stealth tax


Brexit Britain faces a shocking betrayal as the Conservative manifesto fails to provide clarity on the importance of Britain’s fishing waters – which were once the heart of a thriving British industry. The document only promises to ensure control “of the waters where we have historically exercised sovereign control”, suggesting that the Tories may stick with the 12 mile radius allowed by the EU’s job-killing Common Fisheries Policy instead of taking back control of the 200 miles we’re legally entitled to.
Meanwhile, Remoaners at home and Brexit saboteurs in Europe were handed a defeat when the European Court of Justice confirmed that, barring minor exceptions, national parliaments would be unable to veto a trade deal between Britain and the European Union once it’s been concluded by the British government and the European institutions.

Continue reading

Shred-it: More Than Half of UK Business Owners Unaware of Incoming General Data Protection Regulation

Shred-it 2017 Security Tracker Infographic (PRNewsfoto/Shred-it)


LONDON, May 17, 2017 /PRNewswire/ —

Eighty-four per cent of UK small business owners and 43% of senior executives of large companies are unaware of the forthcoming General Data Protection Regulation, according to Shred-it’s seventh annual Security Tracker research, conducted by Ipsos.


Continue reading

Biomarker-based Technologies to Disrupt Conventional Diagnosis in Diabetes Management across the Globe

Personalized treatment to get a boost from the advances in biomarker research, finds Frost & Sullivan’s TechVision team

London – May 17, 2017 – A rising prevalence of diabetes as well as an increasing demand to address future therapies (inhalable insulin, GLP-1 agonists) has driven pharmaceutical companies to intensify focus on biomarker-based research. The companies leverage new biomarker-based platforms for early diagnosis and timely clinical management of diseases such as type 2 diabetes, diabetic kidney disease (DKD), and obesity. “Biomarkers will play a critical role to address the growing demand for personalized treatment strategies,” noted Frost & Sullivan TechVision Research Analyst Vandana Iyer.

Continue reading